StockIQpro
NASDAQ:VERA

Vera Therapeutics, Inc.

Track all markets on TradingView
Track all markets on TradingView

Vera Therapeutics, Inc. reported net income of −$299.6M in fiscal 2025. Free cash flow was −$241.7M, and the diluted share count rose 16.1%.Summary generated from Vera Therapeutics, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROIC−58.0%
Return on equity−50.7%
Debt / equity0.12
Free cash flow−$241.7M
FCF marginn/a
Share count change+16.1%

Financials

Fiscal years, $M
Item20212022202320242025
Revenuen/an/an/an/an/a
Operating income−34−91−102−167−315
Net income−33−89−96−152−300
Free cash flow−24−68−92−136−242

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations